Know Cancer

or
forgot password

A Phase I Study of Weekly Low-Dose Cisplatin Plus Escalating Doses of Oral RAD001(Everolimus) for Patients With Advanced Solid Tumors


Phase 1
18 Years
N/A
Not Enrolling
Both
Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

A Phase I Study of Weekly Low-Dose Cisplatin Plus Escalating Doses of Oral RAD001(Everolimus) for Patients With Advanced Solid Tumors


OBJECTIVES:

Primary

- Determine the recommended phase II dose of everolimus when administered with low-dose
cisplatin in patients with advanced solid tumors.

Secondary

- Determine the safety and tolerability of this regimen in these patients.

- Describe the pharmacokinetics of this regimen in patients with advanced solid tumors.

- Assess the effects of this regimen on p53 and p21 immunohistochemistry assays of pre-
and post-treatment tumor biopsies from patients with recurrent or metastatic solid
tumors.

OUTLINE: This is a dose-escalation study of everolimus (part A) followed by a biological
marker study (part B).

- Part A (closed to accrual as of 1/2009): Patients receive cisplatin* IV over 30 minutes
on days 1, 8, and 15 and oral everolimus* once daily on days 1-21. Treatment repeats
every 28 days for up to 1 year in the absence of disease progression or unacceptable
toxicity.

Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose proceeding that at which 2 of 6
patients experience dose-limiting toxicity (DLT) during course 1. The recommended phase II
dose is defined as the dose at which 1 of 6 patients experience DLT during course 1.

Blood is drawn periodically on days 1 and 8 of course 1 for pharmacokinetic studies.

- NOTE: *Patients who have completed 5 courses of treatment and maintain stable disease
or better may continue treatment with everolimus alone or in combination with cisplatin

- Part B: Patients undergo biopsy of the primary tumor, metastatic deposit, or involved
lymph node. No more than 14 days later, patients receive everolimus at the recommended
phase II dose and cisplatin as in part A.

Patients undergo another tumor biopsy on day 15 of course 1, before receiving chemotherapy.
The pre- and post-therapy tissue is examined by immunochemistry and analyzed for p53 and p21
expression.

PROJECTED ACCRUAL: A total of 30 people will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically confirmed diagnosis of 1 of the following:

- Advanced solid tumor (part A)

- Confirmation by core biopsy or fine-needle aspiration allowed

- Solid tumor (part B)

- Recurrent or metastatic disease

- Easily accessible for biopsy

- Measurable disease

- No uncontrolled brain or leptomeningeal metastases

- No requirement for glucocorticoids

PATIENT CHARACTERISTICS:

- Karnofsky performance status 70-100%

- Absolute neutrophil count ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin > 10 g/dL

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- AST and ALT ≤ 2.5 times ULN (< 5 times ULN if liver metastases are present)

- Creatinine normal OR creatinine clearance ≥ 55 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for at least 3 months
after completion of study therapy

- No HIV positivity

- No peripheral neuropathy ≥ grade 2

- No hypertriglyceridemia ≥ grade 2

- No impaired gastrointestinal function or gastrointestinal disease that may alter the
absorption of everolimus, including any of the following:

- Ulcerative disease

- Uncontrolled nausea

- Vomiting

- Diarrhea

- Malabsorption syndrome

- Small bowel resection

- No other concurrent severe and/or uncontrolled medical disease that would compromise
study participation, including any of the following:

- Uncontrolled diabetes

- Unstable angina

- New York Heart Association class III or IV congestive heart failure

PRIOR CONCURRENT THERAPY:

- No more than 3 prior cytotoxic chemotherapy regimens for recurrent or metastatic
disease

- At least 4 weeks since prior major surgery and recovered

- At least 4 weeks since prior radiation therapy and recovered

- At least 4 weeks since prior systemic anticancer therapy and recovered

- At least 4 weeks since prior and no other concurrent investigational drugs

- No prior everolimus or other agents specifically targeting mTOR

- No prior radiation therapy to > 25% of the bone marrow

- No prior radiation therapy to the whole pelvis and/or brain

- No concurrent chronic steroid treatment (> 5 mg/day of prednisone)

- Concurrent low-dose steroid replacement regimens (≤ 5 mg/day of prednisone)
allowed

- No concurrent immunosuppressive agents

- No other concurrent anticancer agents

- No concurrent agents known to be strong inhibitors or inducers of isoenzyme CYP3A

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Recommended phase II dose of everolimus

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Matthew G. Fury, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

MSKCC 06-129

NCT ID:

NCT00423865

Start Date:

November 2006

Completion Date:

September 2011

Related Keywords:

  • Unspecified Adult Solid Tumor, Protocol Specific
  • unspecified adult solid tumor, protocol specific
  • CISPLATIN
  • RAD001 (EVEROLIMUS)
  • 06-129
  • Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer Center New York, New York  10021